NCT07515599 is a clinical trial in Stage 1 Hypertension, sponsored by Daewoong Pharmaceutical Co. LTD..

Who is sponsoring NCT07515599?

NCT07515599 is sponsored by Daewoong Pharmaceutical Co. LTD..

What condition does NCT07515599 study?

NCT07515599 studies Stage 1 Hypertension.

Is NCT07515599 still recruiting?

NCT07515599 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT07515599

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension

Recruiting now Last updated 7 April 2026

What this trial tests

trial in Stage 1 Hypertension in 12,000 participants. Currently enrolling.

Timeline

17 September 2025

Primary endpoint
31 July 2026

31 January 2027

Quick facts

Lead sponsor	Daewoong Pharmaceutical Co. LTD.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	12,000
Start date	17 September 2025
Primary completion	31 July 2026
Estimated completion	31 January 2027
Sites	1 location across South Korea

Conditions studied

Stage 1 Hypertension — all drugs for Stage 1 Hypertension →

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

19 and older, any sex, with Stage 1 Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07515599 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07515599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing